The application is directed to compounds of formula (I): and their salts and solvates, wherein R.sup.1, R.sup.2, R.sup.3, A.sup.1, A.sup.2, A.sup.3, and n are as set forth in the specification, as well as to a method for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of a lysosomal storage disease, such as Gaucher's, and other diseases or disorders that are synucleinopathies.

##STR00001##

It is related to compounds used as autophagy modulators and a method for preparing and using the same, specifically providing a compound of general formula (I), or pharmaceutically acceptable salts thereof, which is a type of autophagy modulators, particularly mammalian ATG8 homologues modulators. ##STR00001##

Compounds and methods are provided for the treatment of neurological or mitochondrial diseases, including epilepsy. In some embodiments, the compounds are substituted 1,4-naphthoquinones.

Provided is an apparatus for the automated synthesis of at least one chemical compound including: at least one cartridge including at least one first compartment for providing at least one first reagent for the chemical synthesis of the at least one compound; at least one second compartment for providing at least one second reagent for the chemical synthesis of the at least one compound, and at least one third compartment for purifying the at least one synthesized compound; at least one reaction container for providing the compounds to be fed into at least one of the compartments of the cartridge and/or collecting the reaction product from at least one of the compartments of the cartridge; at least one solvent container at least two flow path selecting valves and at least one pump.

Provided is an apparatus for the automated synthesis of at least one chemical compound including: at least one cartridge including at least one first compartment for providing at least one first reagent for the chemical synthesis of the at least one compound; at least one second compartment for providing at least one second reagent for the chemical synthesis of the at least one compound, and at least one third compartment for purifying the at least one synthesized compound; at least one reaction container for providing the compounds to be fed into at least one of the compartments of the cartridge and/or collecting the reaction product from at least one of the compartments of the cartridge; at least one solvent container at least two flow path selecting valves and at least one pump.

Compounds and compositions that can modulate mitochondrial function in neuronal cells are provided herein, as are methods for using the compounds and compositions to treat or prevent conditions such as Alzheimer's disease. For example, compounds of Formula I, compositions containing the compounds, and methods for using the compounds and compositions are provided herein:

##STR00001##

wherein X is absent, CH.sub.2, or C(O); R.sup.1 is H, OH, CN, NO.sub.2, halo, C.sub.1-3 alkyl, C.sub.1-3 haloalkyl, C.sub.1-3 alkoxy, C.sub.1-3 haloalkoxy, C.sub.3-7 cycloalkyl, amino, C.sub.1-3 alkylamino, or di(C.sub.1-3 alkyl)amino; R.sup.2 is H or C.sub.1-6 alkyl; R.sup.3 is H, C.sub.1-6 alkyl, —C(O)(C.sub.1-3 alkyl), or —C(O)O(C.sub.1-3 alkyl); R.sup.4 is C.sub.3-10 cycloalkyl, C.sub.6-10 aryl, 5-10 membered heteroaryl, or 5-10 membered heterocycloalkyl, each optionally substituted by 1, 2, 3, or 4 independently selected R.sup.5 groups; and R.sup.5 is OH, CN, NO.sub.2, halo, C.sub.1-3 alkyl, C.sub.1-3 haloalkyl, C.sub.1-3 alkoxy, C.sub.1-3 haloalkoxy, C.sub.3-7 cycloalkyl, amino, C.sub.1-3 alkylamino, or di(C.sub.1-3 alkyl)amino.

Compounds and compositions that can modulate mitochondrial function in neuronal cells are provided herein, as are methods for using the compounds and compositions to treat or prevent conditions such as Alzheimer's disease. For example, compounds of Formula I, compositions containing the compounds, and methods for using the compounds and compositions are provided herein:

##STR00001##

wherein X is absent, CH.sub.2, or C(O); R.sup.1 is H, OH, CN, NO.sub.2, halo, C.sub.1-3 alkyl, C.sub.1-3 haloalkyl, C.sub.1-3 alkoxy, C.sub.1-3 haloalkoxy, C.sub.3-7 cycloalkyl, amino, C.sub.1-3 alkylamino, or di(C.sub.1-3 alkyl)amino; R.sup.2 is H or C.sub.1-6 alkyl; R.sup.3 is H, C.sub.1-6 alkyl, —C(O)(C.sub.1-3 alkyl), or —C(O)O(C.sub.1-3 alkyl); R.sup.4 is C.sub.3-10 cycloalkyl, C.sub.6-10 aryl, 5-10 membered heteroaryl, or 5-10 membered heterocycloalkyl, each optionally substituted by 1, 2, 3, or 4 independently selected R.sup.5 groups; and R.sup.5 is OH, CN, NO.sub.2, halo, C.sub.1-3 alkyl, C.sub.1-3 haloalkyl, C.sub.1-3 alkoxy, C.sub.1-3 haloalkoxy, C.sub.3-7 cycloalkyl, amino, C.sub.1-3 alkylamino, or di(C.sub.1-3 alkyl)amino.

The application is directed to compounds of formula (I): and their salts and solvates, wherein R.sup.1, R.sup.2, R.sup.3, A.sup.1, A.sup.2, A.sup.3, and n are as set forth in the specification, as well as to a method for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of a lysosomal storage disease, such as Gaucher's, and other diseases or disorders that are synucleinopathies. ##STR00001##

The present invention provides compounds of formula (I) for use in the treatment of respiratory diseases of animals, especially Bovine or Swine Respiratory disease (BRD and SRD).

##STR00001##

Compounds and compositions that can modulate mitochondrial function in neuronal cells are provided herein, as are methods for using the compounds and compositions to treat or prevent conditions such as Alzheimer's disease. For example, compounds of Formula I, compositions containing the compounds, and methods for using the compounds and compositions are provided herein: ##STR00001##
wherein X is absent, CH.sub.2, or C(O); R.sup.1 is H, OH, CN, NO.sub.2, halo, C.sub.1-3 alkyl, C.sub.1-3 haloalkyl, C.sub.1-3 alkoxy, C.sub.1-3 haloalkoxy, C.sub.3-7 cycloalkyl, amino, C.sub.1-3 alkylamino, or di(C.sub.1-3 alkyl)amino; R.sup.2 is H or C.sub.1-6 alkyl; R.sup.3 is H, C.sub.1-6 alkyl, —C(O)(C.sub.1-3 alkyl), or —C(O)O(C.sub.1-3 alkyl); R.sup.4 is C.sub.3-10 cycloalkyl, C.sub.6-10 aryl, 5-10 membered heteroaryl, or 5-10 membered heterocycloalkyl, each optionally substituted by 1, 2, 3, or 4 independently selected R.sup.5 groups; and R.sup.5 is OH, CN, NO.sub.2, halo, C.sub.1-3 alkyl, C.sub.1-3 haloalkyl, C.sub.1-3 alkoxy, C.sub.1-3 haloalkoxy, C.sub.3-7 cycloalkyl, amino, C.sub.1-3 alkylamino, or di(C.sub.1-3 alkyl)amino.